Foghorn Therapeutics Inc.: updates and filings

FHTXNASDAQHealthcare · Pharmaceutical Preparations

Price

$1.79

November 16, 2026Market cap $105M

What Ploutos Investor adds for Foghorn Therapeutics

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 6 fiscal years, from 2020
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • Profit over the last twelve months is well above what the business itself earned, because it includes large gains outside the business, such as on investments or from selling a business. The P/E is lower than the business alone would give.
  • Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 81 daysAround Feb 5, 2027 · for Q4 2026

last Nov 9, 2026next Feb 5, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 11, 2026 latest annualNov 9, 2026 latest quarterly
  • Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 9, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Oct 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Oct 1, 2026Restructuring costs, Regulation FD disclosure
    Form8-K
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 6, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Jun 24, 2026Shareholder vote
    Form8-K
  • May 15, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 14, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 7, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • May 6, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 30, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 30, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 30, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 21, 2026Regulation FD disclosure, other material events
    Form8-K
  • Mar 26, 2026Shares registered for employees
    FormS-8
  • Mar 11, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 11, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Feb 23, 2026Officer or director change, other material events
    Form8-K
  • Jan 13, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Jan 12, 2026Results of operations, Regulation FD disclosure, other material events
    Form8-K
  • Dec 4, 2025Officer or director change
    Form8-K
  • Nov 7, 2025Regulation FD disclosure
    Form8-K
  • Nov 5, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Aug 28, 2020.

The full analysis

What do Foghorn Therapeutics's filings show?

The filings are where every one of Foghorn Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.